ChronTech Pharma AB: Interim Report ChronTech Pharma January-March 2010

STOCKHOLM--(BUSINESS WIRE)-- ChronTech Pharma AB (STO:CTEC):

• Research and development costs amounted to SEK 1.8 (1.1) m

• The loss after tax was SEK -2.7 (-3.5) m

• Earnings per share were SEK -0.04 (-0.10)

• The company had no net sales for the period

• The ChronVac-C® study has been finalized and showed that the therapeutic vaccine is safe and gave positive clinical data. Two patients in the ChronVac-C® study have received one more dose approximately 6-12 months after the fourth vaccination and analysis of the results are ongoing. Five of six patients who after completing the ChronVac-C® study have started treatment according to standard of care, i.e. interferon in combination with ribavirin have responded to the treatment with eradication of the virus already after 4 weeks (so called rapid viral response). This is an unusually rapid reduction of virus in the blood indicating a role for ChronVac-C® in combination therapy

EVENTS AFTER THE END OF THE REPORTING PERIOD

• The multi-center study on one week´s treatment with ChronSeal® is now completed and are now being analysed in Sweden and by Kringle in Japan. ChronTech and Kringle have together decided that the results will be published on May 27th.

About ChronTech
ChronTech develops the therapeutic DNA vaccines ChronVac-C® and ChronVac-B drugs against chronic hepatitis C virus and hepatitis B virus infections, i.e. chronic infections with jaundice causing viruses which can lead to liver cirrhosis and liver cancer. ChronTech has also developed and further develops a patent pending new type of injection needle for a more effective uptake of DNA vaccines. ChronTech also have part ownership in the wound healing therapy ChronSeal®, and in the new platform technology RAS®. The ChronTech share is admitted to trade on First North. Remium AB is Certified Adviser for ChronTech. For more information, please visit: www.chrontech.se

In the event of any discrepancy between the Swedish and English versions of this press release, the Swedish version will take precedence.

This information was brought to you by Cision http://www.cisionwire.com



CONTACT:

ChronTech Pharma AB
Anders Vahlne, CEO and Head of Research
Tel: +46 8 5858 1313
Mobile phone: +46 709 28 05 28,
E-mail: [email protected]

KEYWORDS:   Europe  Sweden

INDUSTRY KEYWORDS:   Health  Biotechnology  Genetics  Pharmaceutical

MEDIA:

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.